Rapport Therapeutics Inc. Common Stock logo

Rapport Therapeutics Inc. Common Stock

RAPP | NASDAQ
Chart Builder DCF Calculator
$38.46
-$1.20 (-3.03%)
Sep 22, 2026, 11:40 AM ET · Market open

Market Data

Market Cap
$1.9B
Enterprise Value
$1.47B
Beta
1.03
Average Volume
340.07K
Shares Outstanding (Diluted)
47.47M
Shares Change YoY
33.94%
Institutional Ownership
N/A
Exchange
NASDAQ
ISIN
US75383L1026

Price Performance

Price Change 1M
-17.6%
Price Change 3M
2.0%
Price Change 6M
37.3%
Price Change YTD
41.1%
Price Change 1Y
51.9%
Price Change 3Y
90.7%
Price Change 5Y
90.7%
1M CAGR (ann.)
-12.8%
1Y CAGR (ann.)
45.0%
5Y CAGR (ann.)
N/A
All-Time CAGR
32.5%

Valuation

PE Ratio
-13.05
Forward PE
N/A
PEG Ratio
0.60
Forward PEG
-0.59
PS Ratio
94.84
Forward PS
N/A
PB Ratio
4.48
P/FCF Ratio
-17.20
P/Adj. FCF Ratio
-13.37
P/OCF Ratio
-19.44
EV/Sales
73.54
EV/EBIT
-9.85
EV/EBITDA
-9.93
EV/FCF
-13.34
Earnings Yield
-7.7%
FCF Yield
-5.8%
Adj. FCF Yield
-7.5%

Financial Health

Net Cash
$436.08M
Total Debt
$10.11M
Cash & Short-Term Investments
$436.08M
Total Assets
$458.98M
Current Ratio
15.72
Quick Ratio
15.72
Debt / Equity Ratio
0.02
Debt / EBITDA
-0.07
Debt / FCF
-0.09
OCF / Debt
-10.86
Interest Coverage
0.00
Altman Z-Score
30.68
Piotroski F-Score
3

Margins & Profitability

Gross Profit Margin
100.0%
Operating Profit Margin
-767.6%
EBITDA Margin
-740.7%
Net Profit Margin
-685.8%
FCF Margin
-551.5%
Adj. FCF Margin
-709.3%
SBC / Revenue
123.0%
SBC Impact (per share)
-28.6%

Returns

Return on Assets
-29.9%
Return on Equity
-29.0%
Return on Invested Capital
-35.5%
Return on Capital Employed
-35.7%
Return on Tangible Assets
-29.9%

Historical Growth (CAGR)

Revenue CAGR 3Y
150.0%
Revenue CAGR 5Y
N/A
Revenue CAGR 10Y
N/A
EPS CAGR 3Y
-54.9%
EPS CAGR 5Y
N/A
EPS CAGR 10Y
N/A
FCF CAGR 3Y
-35.6%
FCF CAGR 5Y
N/A
FCF CAGR 10Y
N/A

Analyst Forecasts

Analyst Rating
Buy
Analyst Count
5
EPS Growth Next 3Y
-28.7%
Revenue Growth Next 3Y
-50.0%
Earnings Date
Nov 4, 2026
EPS Estimate (next Q)
-$1.21
EPS Growth Est (next Q)
70.4%
Revenue Est (next Q)
N/A
Revenue Growth Est (next Q)
N/A

Fair Value Estimates

Graham Number
N/A
Graham Upside
N/A
Lynch Fair Value
N/A
Lynch Upside
N/A
Price Target
$64.80
Price Target Upside
63.4%

Cash Flow

Operating Cash Flow
$-109.74M
Free Cash Flow
$-110.3M
Adj. Free Cash Flow
$-141.85M
FCF Per Share
-$2.05
OCF Per Share
-$2.04
OCF/S Ratio
-483.4%

Income Statement

Revenue
$20M
Gross Profit
$20M
Operating Income
$-153.52M
EBITDA
$-148.14M
Net Income
$-137.16M
EPS (Diluted)
-$3.04
Revenue / Employee
$238.1K
Profit / Employee
$-1.63M
Employees
84

© 2026 bestshares.com. All rights reserved.